DRD4 is the D4 subtype of the dopamine receptor. The D4 subtype is a G-protein coupled receptor which inhibits adenylyl cyclase. It is a target for drugs which treat schizophrenia and Parkinson disease.
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Target:
The synthetic peptide sequence used to generate the antibody AP8760c was selected from the Center region of human DRD4. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
* VAT and and shipping costs not included. Errors and price changes excepted
